Glycemic control and body weight effects of SGLT2 inhibitors (empagliflozin 25 MG, empagliflozin 12.5 MG and dapagliflozin 10 MG) in the treatment of type 2 diabetes mellitus
Abstract
INTRODUCTION/BACKGROUND Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as promising therapeutic agents for the management of type 2 diabetes mellitus (T2DM), offering a novel mechanism of action that targets renal glucose reabsorption.
METHODOLOGYThis study investigates the glycaemic control and body weight effects of SGLT2 inhibitors, specifically empagliflozin 25 mg, empagliflozin 12.5 mg and dapagliflozin 10 mg, in the context of their availability within Hospital Teluk Intan. This is a cross-sectional study which involved patients who had been prescribed SGLT2 inhibitors for a duration exceeding one year. Inclusion criteria encompassed patients meeting the specified duration of SGLT2 inhibitor use, while exclusion criteria comprised individuals with less than one year of SGLT2 inhibitor therapy, those procuring SGLT2 inhibitors independently, those admitted within one year of commencing SGLT2 inhibitors and those lacking documented body weight data due to mobility constraints. Patient records were systematically reviewed to extract demographic details and pertinent clinical parameters, including pre- and post-initiation measurements of glycated haemoglobin (HbA1c), body weight and insulin dosage.
RESULTThe study included 24 patients taking dapagliflozin 25 mg, 14 patients on empagliflozin 12.5 mg and 3 patients on dapagliflozin 10 mg, all meeting the inclusion criteria with available data. Among those on empagliflozin 25 mg, there was no significant…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.